CCDC14 Inhibitors
CCDC14 inhibitors, as per the selected compounds, are chemicals that can directly or indirectly affect the functional activity of the CCDC14 protein. These compounds exert their inhibitory effects by targeting various signaling pathways or biological processes that CCDC14 is known or thought to be involved in. Staurosporine, LY294002, and Y-27632, for instance, inhibit protein kinases, phosphoinositide 3-kinases (PI3Ks), and Rho-associated protein kinases respectively, which are all key components in different signaling pathways. By inhibiting these components, these compounds can disrupt the pathways that regulate CCDC14, leading to its functional inhibition.
Meanwhile, PD98059, Rapamycin, SP600125, SB203580, U0126, BAY 11-7082, Cyclopamine, ZM 336372, and Bortezomib inhibit MEK, mTOR, JNK, p38 MAPK, MEK1 and MEK2, NF-kB activation, Hedgehog signaling, c-Raf, and the 26S proteasome respectively. Each of these targets play a crucial role in a specific signaling pathway or cellular process. Consequently, by inhibiting these targets, these compounds can disrupt the normal functioning of CCDC14. For instance, if CCDC14 relies on the 26S proteasome for its function or regulation, its activity would be inhibited by the disruption of proteasomal degradation caused by Bortezomib. On the other hand, compounds like Cyclopamine inhibit the Hedgehog signaling pathway, and if CCDC14 is part of this pathway, its function can be inhibited by the disruption of Hedgehog signaling.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent protein kinase inhibitor and can inhibit the phosphorylation process in multiple signaling pathways. If CCDC14 is involved in any kinase-dependent pathway, the inhibition of kinase activity by staurosporine can lead to decreased activity or deactivation of CCDC14. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK (Rho-associated protein kinase), a central part of the Rho pathway that influences cell movement and morphology. If CCDC14 is part of this pathway, its function can be inhibited by the disruption of ROCK activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR (mammalian target of Rapamycin), which is a key regulator of cell growth and proliferation. If CCDC14 is involved in these processes, its function can be indirectly inhibited by the disruption of mTOR activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective inhibitor of JNK (c-Jun N-terminal Kinases), which are involved in a wide range of cellular processes. If CCDC14 is part of the JNK pathway, its function can be inhibited by the disruption of JNK activity. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 inhibits NF-kB activation, which can affect numerous proteins downstream in the NF-kB pathway. If CCDC14 is regulated by or part of this pathway, its function can be inhibited by the disruption of NF-kB activity. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Cyclopamine is an inhibitor of the Hedgehog signaling pathway, which is involved in a wide range of cellular processes. If CCDC14 is part of this pathway, its function can be inhibited by the disruption of Hedgehog signaling. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $47.00 | 2 | |
ZM 336372 is a potent inhibitor of the protein kinase c-Raf, which is a part of the Raf/MEK/ERK pathway. If CCDC14 is part of this pathway, its function can be inhibited by the obstruction of c-Raf activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a potent inhibitor of the 26S proteasome, a multiprotein complex involved in protein degradation. If CCDC14 relies on the 26S proteasome for its function or regulation, its activity can be inhibited by the disruption of proteasomal degradation. | ||||||